Clinical trial · no report yet · Phase 3
CLARITY Gastric 01
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06346392 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 43 | |
| YouTube | 3 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Gastric Cancer; Gastroesophageal Junction Cancer
- Interventions
- AZD0901; AZD0901; Ramucirumab+ paclitaxel; Paclitaxel; Docetaxel; Irinotecan; TAS-102; Apatinib
- Arms
- AZD0901 arm 1 · Experimental
- AZD0901 Arm 2 · Experimental
- Investigator's choice arm · Active comparator
- Enrollment
- 594
- Primary outcomes
- Progression Free Survival (PFS) in all randomized participants
- Overall Survival (OS) for 3L+ participants
- Sponsor
- AstraZeneca
- Start
- Mar 4, 2024
- Primary completion
- May 31, 2026
- Results posted
- No
- Registry record
- NCT06346392 · updated Oct 15, 2026
Publications
linked from the registry- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124
- Xu G, Liu W, Wang Y, Wei X, Liu F, He Y, Zhang L, Song Q, Li Z, Wang C, Xu R, Chen B. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 2024 Sep 17;5(9):101710. doi: 10.1016/j.xcrm.2024.101710. Epub 2024 Sep 3. PubMed 39232496